MMP9 and lung carcinoma: In this study, we successfully fused A549 Cm with MMP-9-switchable peptide-based charge-reversal liposome membranes and prepared integrated hybrid nanovesicle–cancer liposome-coated NPs for treating lung cancer in vivo.